422 related articles for article (PubMed ID: 18806701)
1. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Tursi A
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
[TBL] [Abstract][Full Text] [Related]
2. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
3. Balsalazide in treating colonic diseases.
Tursi A
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1555-63. PubMed ID: 19708827
[TBL] [Abstract][Full Text] [Related]
4. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W; Aiello F
Int J Colorectal Dis; 2007 Sep; 22(9):1103-8. PubMed ID: 17390144
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
6. Balsalazide disodium for the treatment of ulcerative colitis.
Patil SA; Moss AC
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):177-84. PubMed ID: 19072352
[TBL] [Abstract][Full Text] [Related]
7. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
8. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Wiggins JB; Rajapakse R
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1279-84. PubMed ID: 19743890
[TBL] [Abstract][Full Text] [Related]
9. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
10. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
11. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
Drugs; 2006; 66(10):1371-87. PubMed ID: 16903771
[TBL] [Abstract][Full Text] [Related]
12. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
15. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
[TBL] [Abstract][Full Text] [Related]
16. [Ulcerative colitis. Complementary therapies].
Matthes H; Moser G; Jantschek G
Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
[No Abstract] [Full Text] [Related]
17. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
BioDrugs; 2007; 21(1):61-3. PubMed ID: 17263590
[TBL] [Abstract][Full Text] [Related]
18. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
20. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
